Contribute Try STAT+ Today

A California law that banned coupons for brand-name prescription drugs failed to significantly boost greater use of cheaper generics during its first year, according to a new analysis.

The law, which went into effect in January 2018, was one of many gambits by state officials to control the rising cost of prescription drugs. Coupons made an attractive target. Drug makers argue that they lower out-of-pocket expenses for consumers, but critics say coupons are slick marketing tools used to promote higher-cost medicines and eventually, cost the overall health system more money.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment